Co-DiagnosticsCODX
Market Cap: $42.8M
About: Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Employees: 155
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
18% more capital invested
Capital invested by funds: $4.91M [Q1] → $5.81M (+$896K) [Q2]
13% more funds holding
Funds holding: 39 [Q1] → 44 (+5) [Q2]
0.84% more ownership
Funds ownership: 14.0% [Q1] → 14.84% (+0.84%) [Q2]
69% less call options, than puts
Call options by funds: $79K | Put options by funds: $252K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target | 12%upside $1.50 | Neutral Maintained | 12 Aug 2024 |
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target | 49%upside $2 | Neutral Reiterated | 17 Jun 2024 |
Financial journalist opinion
Based on 3 articles about CODX published over the past 30 days